ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0795

Prevalence of Post-exertional Malaise (PEM) in Adults with Rheumatic Diseases and Relationship with COVID19 Infection

Kaleb Michaud1, Shreena Kamlesh Gandhi2, Sofia Pedro3, Cassandra Calabrese4, Patti Katz5 and Leonard Calabrese6, 1University of Nebraska Medical Center, Omaha, NE, 2Kansas University School of Medicine - Wichita, Wichita, KS, 3Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 4Cleveland Clinic Foundation, Cleveland Heights, OH, 5UCSF, San Rafael, CA, 6Cleveland Clinic, Cleveland, OH

Meeting: ACR Convergence 2024

Keywords: COVID-19, Fatigue, fibromyalgia, Patient reported outcomes, registry

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: Pain in Rheumatic Disease Including Fibromyalgia

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Chronic fatigue is the dominant symptom in patients with Long COVID and Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS) as well as an important and prevalent symptom among patients with rheumatic diseases. Understanding the nature and interrelationship of the fatigue among these disorders is important both for epidemiologic understanding and clinical management. A cardinal and putative distinguishing feature of the fatigue present in patients with Long COVID and ME/CFS from other fatiguing states is the presence of post-exertional malaise (PEM) which refers to a worsening of fatigue and other fatigue related symptoms after exertion which was previously tolerated and often delayed 24-72 hours or more1. PEM has not been systematically investigated in rheumatic diseases and insights into its prevalence is an important initial step in further defining its nature and relationships of fatigue in these conditions compared to Long COVID and ME/CFS. The current study utilizing a validated instrument2 for the detection of PEM represents the first effort to define its prevalence across rheumatic diseases states and its relationship to COVID19 infection status.

Methods: Adult participants in the Forward Databank with rheumatic diseases completed comprehensive questionnaires including the PEM subscale questions from the DePaul

Symptom Questionnaire from January through June 2024. PEM+ was defined as having at least a frequency ≥2 and simultaneously a severity ≥2 in any item on the survey. We categorized diagnoses into RA, OA, FMS, and SLE, and additionally those who met the 2016 Fibromyalgia criteria (FMS16) independent of primary diagnoses. Additional items included details of COVID19 infection, Long COVID diagnosis, and comorbidities.

Results: A total of 1158 participants completed the PEM questionnaire with 7.5% PEM+ (4.4% OA to 14% FMS, Table 1). The highest prevalence of 20% was associated with those meeting FMS16. While any prior COVID19 infection was associated with PEM+, more recent and hospitalized COVID19, and Long COVID diagnoses had higher PEM+. Table 2 shows association with PEM+ with worse health and disease symptoms including depression and widespread pain. In contrast, younger age was associated with PEM+. In addition, we present the breakdown of PEM items selected for those PEM+ in Table 3.

Conclusion: This is the first study we are aware of that presents PEM rates in a RMD population. We found important associations with PEM status including disease activity and COVID19 infection exposure that require additional understanding notably around the use of graded exercise.
 

References:

1. Appelman, B, Charlton, B.T., Goulding, R.P. et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat Commun 15, 17 (2024). https://doi.org/10.1038/s41467-023-44432-3

2. Cotler, J., Holtzman, C., Dudun, C. & Jason, L. A. A brief questionnaire to assess post-exertional malaise. Diagnostics 8, 66 (2018). https://doi.org/10.3390/diagnostics8030066

Supporting image 1

Table 1 – Prevalence of PEM+ in 2024 by RMD diagnosis and COVID19 status

Supporting image 2

Table 2 – Characteristics by PEM+ status

Supporting image 3

Table 3 – Distribution of PEM component items selected by PEM+ and RMD category


Disclosures: K. Michaud: None; S. Gandhi: None; S. Pedro: None; C. Calabrese: AstraZeneca, 2, 6, sanofi, 2, 6; P. Katz: None; L. Calabrese: Amgen, 2, 6, AstraZeneca, 2, jansen, 2, sanofi, 2, UCB, 2, 6.

To cite this abstract in AMA style:

Michaud K, Gandhi S, Pedro S, Calabrese C, Katz P, Calabrese L. Prevalence of Post-exertional Malaise (PEM) in Adults with Rheumatic Diseases and Relationship with COVID19 Infection [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-post-exertional-malaise-pem-in-adults-with-rheumatic-diseases-and-relationship-with-covid19-infection/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-post-exertional-malaise-pem-in-adults-with-rheumatic-diseases-and-relationship-with-covid19-infection/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology